Replies to post #355427 on NorthWest Biotherapeutics Inc (NWBO)

[Dan88]

Exactly troc. It's one more sign built upon the general understanding or good practice that if the trial failed (I would deem a trial fails if it failed to meet its primary endpoint even later the underlying treatment could be approved from other strong indication), the company should have notified the general public.

Of course the blended blinded data says otherwise;

The revised reordered the endpoint suggests otherwise;

And even the current market cap, despite well undervalued, says otherwise.

GL.

[exwannabe]

Troc, a failed trial does not mean the drug does not work. Does not even imply it.

DNDN failed their trials in 2006 yet many correctly assumed from the results that the Provenge probably worked. Just not enough evidence for approval.

Many patients were treated with Provenge after the 2006 trial failures and prior to approval.

[Dr Bala]

Troc, the UCLA Medical School is behind DCVax-L.

Look at the following quotes during the talks by Dr. Linda Liau and Dr. Leia Nghiemphu.

Dr. Linda Liau (Fellow of the National Academy of Medicine) talking about the DCVax-L therapy at the UAB on November 6th, 2020: "It is good for the patients."

Dr. Leia Nghiemphu of the UCLA School of Medicine on December 4th, 2020 at the UCLA Brain Tumor Virtual Conference: "There are many different types of vaccines... Here at UCLA, we use the dendritic cell vaccine."

UCLA is a top medical school and I don't think they will be using DCVax-L unless they know that it works.

The chance of a failed trial is 0%, imo.